ABSTRACT
The European New Car Assessment Programme (Euro NCAP), the Insurance Institute for Highway Safety (IIHS), and the U.S. National Highway Traffic Safety Administration (NHTSA) each publish safety ratings of new passenger vehicles based on crash test results and crash avoidance technology soon after they are introduced into the market. IIHS alone singles out vehicles for “Top Safety Pick”. The Institute also periodically lists driver death rates of vehicles during their first few years of use, accompanied by assertions that larger, heavier passenger vehicles are safer. Median death rates by vehicle size in the Institute’s data do not support the assertion. This study examines the association of vehicle weight to the risk of all deaths in fatal crashes where specific makes and models were involved, controlling statistically for the Institute’s vehicle safety ratings as well as NHTSA ratings of full-frontal crash tests and rollover propensity, lane retention warnings, adaptive cruise control, and automatic braking. Increased weight is slightly related to a lower fatal risk in the 2014-2017 models but not the 2018-2019 models. Lane retention warnings and IIHS’s higher ratings of crashworthiness are related to reduced death risk. Adaptive cruise control is not associated with fatal crash risk. Automatic emergency braking (AEB) technology rated “superior” is a criterion for an IIHS “Top Safety Pick” but it is correlated to higher fatal crash involvement of vehicles that have the technology as optional or standard equipment. IIHS tests of AEB systems are conducted only at low speeds. The statistical results are not definitive but suggest that a rating system based on modeling death risk prediction from more detailed data from various tests such as Euro NCAP tests of AEB systems could better inform consumer choice of vehicles.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data are from public downloadable file referenced in the manuscript.
